Literature DB >> 27240994

Dacomitinib versus erlotinib in patients with EGFR-mutated advanced nonsmall-cell lung cancer (NSCLC): pooled subset analyses from two randomized trials.

S S Ramalingam, K O'Byrne, M Boyer, T Mok, P A Jänne, H Zhang, J Liang, I Taylor, E I Sbar, L Paz-Ares.   

Abstract

Entities:  

Year:  2016        PMID： 27240994     DOI： 10.1093/annonc/mdw221

Source DB:  PubMed          Journal:  Ann Oncol        ISSN： 0923-7534            Impact factor:   32.976


× No keyword cloud information.
  3 in total

Review 1.  Second-line Treatment of Non-Small Cell Lung Cancer: Focus on the Clinical Development of Dacomitinib.

Authors:  Jon Zugazagoitia; Asunción Díaz; Elisabeth Jimenez; Juan Antonio Nuñez; Lara Iglesias; Santiago Ponce-Aix; Luis Paz-Ares
Journal:  Front Med (Lausanne)       Date:  2017-04-05

2.  Complex EGFR mutations in non-small cell lung cancer: a distinct entity?

Authors:  Michał Bieńkowski; Rafał Dziadziuszko; Jacek Jassem
Journal:  J Thorac Dis       Date:  2022-08       Impact factor: 3.005

Review 3.  Emerging therapeutic agents for lung cancer.

Authors:  Bhagirathbhai Dholaria; William Hammond; Amanda Shreders; Yanyan Lou
Journal:  J Hematol Oncol       Date:  2016-12-09       Impact factor: 17.388
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.